Theralink

Theralink(r) tumor biomarker platform

The Theralink assay technology uses reverse phase protein array (RPPA) technology to measure the quantity, activity and downstream signaling pathway activation levels for receptors of FDA-approved and investigational drugs in order to determine whether or not a prescribed medication is likely to be effective in treating the cancer of a specific patient at that moment in time.

This highly sensitive analysis empowers physicians to make better treatment decisions by giving a greater degree of certainty as to whether a specific drug will work in treating a specific patient, as well as informing a physician whether a chemotherapy treatment is unlikely to be effective. This information potentially allows the patient to forego the devastating side effects of cytotoxic treatments that are unlikely to deliver clinically meaningful benefit, while guiding physicians to prescribing treatments likely to yield maximum benefit.
 
Theralink measures phosphorylated proteins in tumor tissue. Phosphorylated proteins represent active targets for drugs. For further information please visit the website of Avant's wholly-owned subsidiary Theranostics Health in which the technology is housed at www.theranosticshealth.com

  • BREAST CANCER
  • OVARIAN CANCER
  • PANCREATIC CANCER
  • COLORECTAL CANCER

OvaDx (tm) diagnostic blood test for ovarian cancer

Ovarian cancer is known as the “silent killer” due to its often being identified during its later stages. Early stage symptoms are often ignored, but early detection has a 5-year survivability rate of 93%. Late stage symptoms are more easily detected, but have a 5-year survivability rate of 18%. OvaDx is in early stage development as a potential replacement to CA-125.

LymPro Test(tm)

The LymPro Test is a blood test for Alzheimer's disease that measures immune system dysfunction in the blood that is indicative of a likely Alzheimer's diagnosis. LymPro is currently being evaluated as an early-stage diagnostic screening test for Alzheimer's disease, and is also being evaluated in Chronic Traumatic Encephalopathy (CTE) that results from chronic sub-concussive blows to the brain.

Next Generation Sequencing Autoimmune platform